Evidence map›Paper›PMID 30984386›Full record

ArticleF1000Research2019

Assessing drug target suitability using TargetMine.

Yi-An Chen, Erika Yogo, Naoko Kurihara, Tomoshige Ohno, Chihiro Higuchi, Masatomo Rokushima, Kenji Mizuguchi

Abstract read
In one paragraph

Article in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi-An ChenNational Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, 5670085, Japan.ORCID 0000-0003-4936-8060
Erika YogoShionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka, 5610825, Japan.
Naoko KuriharaShionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka, 5610825, Japan.
Tomoshige OhnoShionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka, 5610825, Japan.
Chihiro HiguchiNational Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, 5670085, Japan.
Masatomo RokushimaShionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka, 5610825, Japan.
Kenji MizuguchiNational Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, 5670085, Japan.ORCID 0000-0003-3021-7078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In selecting drug target candidates for pharmaceutical research, the linkage to disease and the tractability of the target are two important factors that can ultimately determine the drug efficacy. Several existing resources can provide gene-disease associations, but determining whether such a list of genes are attractive drug targets often requires further information gathering and analysis. In addition, few resources provide the information required to evaluate the tractability of a target. To address these issues, we have updated TargetMine, a data warehouse for assisting target prioritization, by integrating new data sources for gene-disease associations and enhancing functionalities for target assessment. As a data mining platform that integrates a variety of data sources, including protein structures and chemical compounds, TargetMine now offers a powerful and flexible interface for constructing queries to check genetic evidence, tractability and other relevant features for the candidate genes. We demonstrate these features by using several specific examples.

Indexed as

Data MiningDrug DevelopmentProteinsProteinsdiseasedrug assessmentgenetic variationtractability

Identifiers

PMID30984386
PMCPMC6439796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.